Isotretinoin: State of the art treatment for acne vulgaris

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue SUPPL. 1, 2010, Pages

  Ganceviciene, Ruta ^c   Zouboulis, Christos C ^a,b  

^a DESSAU MEDICAL CENTER   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NONE

Author keywords

Akne; Isotretinoin; Retinoide

Indexed keywords

ACCUNETAN; ACCURAN; ACCURE; ACNENORMIN; ACNETANE; ACNETRETIN; ACNIL; ACNOTIN; ACNOTREN; AKNAL; AKNEFUG; ALCOHOL; AMNESTEEM; CECNOIN; CISCUTAN; CURACNE; CURATANE; DERCUTANE; DOXYCYCLINE; GENERIC DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOACNE; ISODERM; ISOFACE; ISOHEXAL; ISOTRETINOIN; ISOTROIN; LIDERMA; MATRIX METALLOPROTEINASE; MINOCYCLINE; RETINOL; TETRACYCLINE; TRETIN; TRETINAC; TRIVANE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ACNE VULGARIS; ALOPECIA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; BLURRED VISION; BONE ATROPHY; BONE DEMINERALIZATION; BRAIN PSEUDOTUMOR; CATARACT; CHEILITIS; CONJUNCTIVITIS; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; FIRST PASS EFFECT; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERLIPIDEMIA; HYPEROSTOSIS; INTRACRANIAL HYPERTENSION; KERATINIZATION; LEUKOPENIA; LIVER TOXICITY; MYALGIA; NAUSEA AND VOMITING; NIGHT BLINDNESS; PAPILLEDEMA; PHARMACODYNAMICS; PHOTOSENSITIVITY; PROPIONIBACTERIUM ACNES; SEBUM SECRETION; SKIN FRAGILITY; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOCYTOSIS; XEROPHTHALMIA; XEROSIS;

EID: 77951431196     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07238.x     Document Type: Article

References (78)

1. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J. Am. Acad. Dermatol. 41, 577-580 (1999).
2. Zouboulis C. Retinoids: is there a new approach? IFSCC Magazine 3(3), 9-19 (2000). * Provides better understanding of retinoid function at the molecular level, explains selective retinoid receptor agonist activity in the topical treatment of dermatological diseases.
3. Kuenzli S, Saurat J-H. Retinoids. In: Dermatology (Volume 2). Bolognia JL, Jorizzo JL, Rapini RP (Eds). Mosby, London, UK, 1991-1996 (2003). * Current knowledge on retinoids and their functions.
4. Benifla JL, Ville Y, Imbert MC, Frydman R, Thomas A, Pons JC. Fetal tissue dosages of retinoids: experimental study concerning a case of isotretinoin (Roaccutan) administration and pregnancy. Fetal Diagn. Ther. 10, 189-191 (1995).
5. Matsuoka LY, Wortsman J, Tang G et al. Are endogenous retinoids involved in the pathogenesis of acne? Arch. Dermatol. 127, 1072-1073 (1991).
6. Blaner WS, Olson JA. Retinol and retinoic acid metabolism. In: The Retinoids. Biology, Chemistry, and Medicine (3rd Edition). Raven Press, NY, USA, 229-256 (1994). * - Provides bright knowledge on the biochemistry of retinoids.
7. Rollmann O, Vahlquist A. Oral isotretinoin (13-rfi-retinoic acid) therapy in severe acne: drug and vitamin A concentrations in serum and skin. J. Invest. Dermatol. 86, 384-389 (1986).
8. Roos TC, Jugert FK, Merk HF, Bickers DR. Retinoid metabolism in the skin. Pharm. Rev. 50, 315-333 (1998).
9. Zouboulis CC. Exploration of retinoid activity and the role of inflammation in acne: issues affecting future directions for acne therapy J. Eur. Acad. Dermatol. Venereol. 15, 63-67 (2001). * Summarizes new results concerning new therapeutic concepts for the treatment of patients with acne.
10. Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhoea and acne. Dermatology 196, 140-147 (1998). ** - Summary of the clinical aspects of administration of systemic isotretinoin.
11. Kistler A. Limb bud cell cultures for estimating the teratogenic potential of compounds: validation of the test system with retinoids. Arch. Toxicol. 60, 403-414 (1987). * - Opens the cellular mechanisms of action of the natural and the synthetic retinoids and provides information on retinoid teratogenicity.
12. Orfanos CE, Zouboulis CC, Almond Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 53, 358-388 (1997). ** - Comprehensive information on all fields of retinoid function.
13. Landthaler M, Kummermehr J, Wagner A, Plewig G. Inhibitory effects of 13 -cis-retinoic acid on human sebaceous glands. Arch. Dermatol. Res. 269, 297-309(1980).
14. Melnik B, Kinner T, Plewig G. Influence of oral isotretinoin treatment on the composition of comedonal lipids. Implications for comedogenesis in acne vulgaris. Arch. Dermatol. Res. 280, 97-102 (1988).
15. Zouboulis CC, Krieter A, Gollnick H, Orfanos CE. Progressive differentiation of human sebocytes in vitro h characterized by increased cell size and altered antigenic expression and is regulated by culture duration and retinoids. Exp. Dermatol. 3, 151-160(1994).
16. Zouboulis CC, Korge B, Akamatsu H et al. Effects of 13-os-retinoic acid, alltrans- retinoic acid and acitretin on the proliferation, lipid synthesis and keratin expression of cultured human sebocytes in vitro. J. Invest. Dermatol. 96, 792-797 (1991). ** - Gives a wide overview of the cellular mechanisms of isotretinoin activity.
17. Zouboulis CC, Xia L, Korge B, Gollnick H, Orfanos CE. Cultivation of human sebocytes in vitro: cell characterization and influence of synthetic retinoids. In: Retinoids: 10 Years On. Saurai J H (Ed.). Karger, Basel, Switzerland, 254-273 (1991).
18. Geiger JM. Retinoids and sebaceous gland activity. Dermatology 191, 305-310(1995).
19. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 206, 37-53 (2003). * - Expands perception of acne treatment essentials. (Pubitemid 36164665)
20. King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13 -cis-retinoic acid on acne, sebum excretion rate and microbial population. Br. J. Dermatol. 107, 583590 (1982).
21. Adams J, Kiss E, Arroyo ABV et al. 13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. Am. J. Pathol. 167, 285-298 (2005). ** - Opens new horizons for 13-cis retinoic acid effectiveness.
22. Zouboulis CC. Retinoids - which dermatological indications will benefit in the near future? Skin Pharmacol. Appl. Skin Physiol. 14, 303-315 (2001). ** Expands perception of retinoid administration in dermatology.
23. Zouboulis CC. Isotretinoin revisited pluripotent effects on human sebaceous gland cells. J. Invest. Dermatol. 126, 2154-2156 (2006). ** - Explains the molecular and biological background of isotretinoin effects on human sebaceous gland cells.
24. Tsukada M, Schröder M, Roos TC et al. 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J. Invest. Dermatol. 115, 321-327 (2000). * - Explains the sebocyte-specific activity of 13-as retinoic acid and supports a pro-drugdrug relation between 13-cis retinoic acid and all-trans retinoic acid.
25. Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis retinoic acid induces apoptosis and cell cycle arrest in human SEB 1 sebocytes. J. Invest. Dermatol. 126, 2178-2189 (2006). * Provides further explanations of the the sebosuppressive effect and the resolution of acne by 13-cis retinoic acid.
26. Kang S, Cho S, Chung JH et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-KB and activator protein-1 in inflammatory acne lesions in in vivo. Am. J. Pathol. 166, 1691-1699 (2005). (Pubitemid 40734392)
27. Papakonstantinou E, Aletras AJ, Glass E et al. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J. Invest. Dermatol. 125, 673-684 (2005). * - Provides evidence regarding the involvement of matrix metalloproteinases in acne pathogenesis and explains the major contribution of isotretinoin to the therapeutic effect in acne.
28. Guy R, Ridden C, Kealey T. The improved organ maintenance of the human sebaceous gland: modeling in vitro the effects of epidermal growth factor, androgens, estrogens, 13-cis retinoic acid, and phenol red. J. Invest. Dermatol. 106, 454-460 (1996).
29. Karlsson T, Vahlquist A, Kedishvili N, Torma H. 13-cis-retinoic acid competitively inhibits 3 a- hydroxysteroid oxidation by retinol dehydrogenase RoDH 4: a mechanism for its anti-androgenic effects in sebaceous glands? Biochem. Biophys. Res. Commun. 303, 273-278 (2003). * - Explains the possible molecular pathway of the 13-os-retinoic acid anti-androgenic effect.
30. Zouboulis CC, Korge B, Mischke D, Orfanos CE. Altered proliferation, synthetic activity, and differentiation of cultured human sebocytes in the absence of Vitamin A and their modulation by synthetic retinoids. J. Invest. Dermatol. 101, 628-633 (1993). * Explains the differences of action among vitamin A and synthetic retinoids on cultured human sebocytes. 31 Downie MMT, Sanders DA, Kealey T. Modelling the remission of individual acne lesions in vitro. Br. J. Dermatol. 147, 869-878 (2002). (Pubitemid 23285866)
31. Norris DA, Osborn R, Robinson W, Tonnesen MG. Isotretinoin produces significant inhibition of monocyte and neutrophil Chemotaxis in vivo in patients with cystic acne. J. Invest. Dermatol. 89, 38-43 (1987).
32. Orfanos CE, Bauer R. Evidence for anti- inflammatory activities of oral synthetic retinoids: experimental findings and clinical experience. Br. J. Dermatol. 109, 55-60 (1983).
33. Goldman, R. Effect of retinoic acid on the proliferation and phagocytic capability of murine macrophage-like cell lines. J. Cell. Physiol. 120, 91-102 (1984).
34. Holland DB, Jeremy AH, Roberts SG et al. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. Br. J. Dermatol. 150, 72-81 (2004). * - Reports on the influence of retinoids on the scarring process of acne lesions.
35. Bécherel PA, Mossalayi MD, LeGoff L et al. Mechanism of anti-inflammatory action of retinoids on keratinocytes. Lancet 344, 1570-1571 (1994).
36. Boman HG. Gene-encoded peptide antibiotics and the concept of innate immunity: an update review. Scand. J. Immunol. 48, 15-25(1998).
37. Zanetti M, Litteri L, Gennaro R, Horstmann H, Romeo D. Bactenecins, defense polypeptides of bovine neutrophils are generated from precursor molecules stored in the large granules. J. Cell. Biol. 111, 1363-1371 (1990).
38. Frohm M, Agerberth B, Ahangari G et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272, 15258-15263 (1997).
39. Wu H, Zhang G, Minton JE et al. Regulation of cathelicidin gene expression: induction by lipopolysaccharide, interleukin-6, retinoic acid, and Salmonella enterica serovar typhimurium infection. Infect. Immun. 68, 5552-5558 (2000).
40. Layton AM, Dreno B, Gollnick HPM, Zouboulis CC. A review of the European directive for prescribing systemic isotretinoin for acne vulgaris. J. Eur. Acad. Dermatol. Venereol. 20, 773-776 (2006). ** - Comments on the positive and negative angles of the European directive for prescribing systemic isotretinoin for acne vulgaris.
41. Zouboulis CC. Acne: current aspects on pathology and treatment. Dermatol. Experiences 1, 6-37 (1999). ** - Clinical aspects of acne and its treatment.
42. Zouboulis CC, Orfanos CE. Retinoids. In: Drug Therapy in Dermatology. Millikan LE (Ed.). Marcel Dekker, NY, USA, 171-233 (2000). ** - Represents a comprehensive review of the treatment possibilities with retinoids in dermatological practice.
43. Caputo R, Cavicchini S, Cooper A et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 194, 351-357 (1997). ** - Provides probative facts about the treatment with Roaccutane® (Pubitemid 27290560)
44. Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J. Am. Acad. Dermatol. 27, S2-S7 (1992). ** - Helps to expand knowledge about the treatment with Roaccutane.
45. Seukeran DC, Cunliffe WJ. Acne vulgaris in the elderly: the response to lowdose isotretinoin. Br. J. Dermatol. 139, 99-101 (1998). * - Helps to expand knowledge about the treatment with Roaccutane.
46. Georgarakis M, Zougrou F, Tzavara S, Kontopoulos G, Tsiptsios I. Comparative bioequivalence study of two isotretinoin soft gel capsule formulations in healthy male volunteers. Int. J. Clin. Pharmacol. Therapeutics 41, 316-322 (2003). ** Indicates differences between generic isotretinoin preparations and Roaccutane.
47. Taylor PW, Keenan MHJ. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane. Cur. Med. Res. Opin. 22, 603-615 (2006). ** - Indicates differences between generic isotretinoin preparations and Roaccutane.
48. James WD. Acne. N. Engl. J. Med. 352, 1463-1472 (2005).
49. Layton AM. A review on the treatment of acne vulgaris. Int. J. Clin. Pract. 60, 64-72 (2006). * - Useful review for the clinical workout.
50. Stainford JM, Layton AM, Taylor JP et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br. J. Dermatol. 129, 297-301 (1993). ** - Helps to expand knowledge on the treatment with isotretinoin.
51. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris 10 years later: a safe and successful treatment. Br. J. Dermatol. 129, 292-296 (1993). * - Explains reasonably safety and effectiveness of systemic isotretinoin administration in acne vulgaris.
52. Goulden V, Clark SM, McGeown C et al. Treatment of acne with intermittent isotretinoin. Br. J. Dermatol. 137, 106-108 (1997). * - Helps to expand knowledge on the treatment with isotretinoin.
53. Zouboulis CC. The truth behind this undeniable efficacy - recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 212, 99-100 (2006). ** - Summarizes the limits of isotretinoin effectiveness and the relapse risk factors in acne treatment with oral isotretinoin.
54. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N. Engl. J. Med. 333, 101-106(1995).
55. Wessels F, Anderson AN, Kropman K. The cost-effectiveness of isotretinoin in the treatment of acne. Part 3. A cost minimisation pharmaco-economic model. S. Afr. Med. J. 89, 791-794 (1999).
56. Newton JN. How cost-effective is oral isotretinoin? Dermatology 195, 38-40 (1997). * - Summarizes the cost-effectiveness issue comparing systemic isotretinoin administration with other antiacne treatments.
57. Lee ML, Cooper A. Isotretinoin: cost benefit study. Australas. J. Dermatol. 32, 17-20 (1991).
58. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J. Am. Acad. Dermatol. 45, 150-157 (2001). * - Overviews useful information for clinician's work concerning administration and possible complications of isotretinoin therapy.
59. Goulden V, Layton AM, Cunliffe WJ. Longterm safety of isotretinoin as a treatment for acne vulgaris. Br. J. Dermatol. 131, 360-363 (1994). ** - Helps to expand knowledge on the treatment with isotretinoin.
60. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia arreata, atopic dermatitis and psoriasis. Br. J. Dermatol. 139, 846-850(1998).
61. Jick SS, Kremers HM, Vasilakis Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch. Dermatol. 136, 1231-1236 (2000). * - Metaanalysis of cohort studies on the use of isotretinoin and the risk for depression, suicide or other psychiatric disorders.
62. Rubinow DR, Peck GL, Squillace KM, Gantt GG. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J. Am. Acad. Dermatol. 17, 25-32 (1987).
63. Ng CH, Schweitzer I. The association between depression and isotretinoin use in acne. Aust. NZ J. Psychiatry 37, 78-84 (2003).
64. De Marchi MA, Maranhao RC, Brandizzi LI, Souza DR. Effects of isotretinoin on the metabolism of triglyceriderich lipoproteins and on the lipid profile in patients with acne. Arch. Dermatol. Res. 297, 403-408 (2006).
65. Edian-Quan HN, Wolverton S. Systemic retinoids. In: Comprehensive Dermatology Drug Therapy. Wolverton SE (Ed.). WB Sauders, PA, USA, 269-310 (2001).
66. Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 132, 299-305 (2001). (Pubitemid 32768596)
67. Ling TC, Parkin G, Islam J et al. What is the cumulative effect of long-term, low dose isotretinoin on the development of DISH? Br. J. Dermatol. 144, 630-632 (2001). (Pubitemid 32232030)
68. Liebler S, Uberschar B, Kubert H et al. Renal retinoid system: time-dependent activation in experimental glomerulonephritis. Am. J. Physiol. Renal. Physiol. 286, F458-F465 (2004). * - Helps to expand knowledge on retinoid action and therapeutic potential.
69. Zouboulis CC, Eady A, Philpott M et al. What is the pathogenesis of acne? Exp. Dermatol. 14, 143-152 (2005). ** - Presents classical and modern aspects of acne pathogenesis.
70. Zouboulis CC. Therapie der Akne mit Antiandrogenen - Eine evidenzbasierte Übersicht. J. Dtsch. Dermatol. Ges. 1, 535-546 (2003).
71. Zouboulis CC, Nestoris S, Adler YD et al. A new concept for acne therapy: a pilot study with zileuton, an oral 5 lipoxygenase inhibitor. Arch. Dermatol. 139, 668-670 (2003). ** - Correlates the new aspects of acne pathogenesis with a new option for acne therapy.
72. Zouboulis CC, Saborowski A, Boschnakow A. Zileuton, an oral 5 lipoxygenase inhibitor, directly reduces sebum production. Dermatology 210, 36-38 (2005). ** - Correlates the new aspects of acne pathogenesis with a new option for acne therapy. (Pubitemid 39656717)
73. Nagy I, Pivarcsi A, Kis K et al. Propionibacterium acnes and lipopolysaccharide induce the expression of antibacterial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect. 8, 2195-2205 (2006). ** - Expands perception of acne pathogenesis and indicate a new therapeutic possibility.
74. Lee D Y, Yamasaki K, Zouboulis CC et al. Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill Propionibacterium acnes. J. Invest. Dermatol. (2007) (In Press). ** - Expands perception of acne pathogenesis and indicate a new therapeutic possibility.
75. Thielitz A, Reinhold D, Vetter R et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD 13) target major pathogenetic steps in acne initiation. J. Invest. Dermatol. 127, 1042-1051 (2007). ** - Expands perception of acne pathogenesis and indicate a new therapeutic possibility.
76. Hong I, Lee M H, Na T Y et al. LXRα enhances lipid synthesis in SZ95 sebocytes. J. Invest. Dermatol (2007) (In Press). ** - Expands perception of acne pathogenesis and indicate a new therapeutic possibility.
77. Georgel P, Crozat K, Lauth X et al. A TLR2 responsive lipid effector pathway protects mammals against Gram-positive bacterial skin infections. Infect. Immun. 73, 4512-4521 (2005). ** - Demonstrates an important role of a TLR2 in bacterial skin infection development and in lipogenesis.
78. Alestas T, Ganceviciene R, Fimmel et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J. Mol. Med. 84, 75-87 (2006). ** - Provides an explanation of the role of inflammation in acne and opens a new viewpoint of acne pathogenesis.